

Dale Bixby

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/902431/publications.pdf>

Version: 2024-02-01

26
papers

1,471
citations

687363
13
h-index

642732
23
g-index

26
all docs

26
docs citations

26
times ranked

2509
citing authors

| # | ARTICLE | IF | CITATIONS |
|----|--|------|-----------|
| 1 | Acute Myeloid Leukemia, Version 3.2017, NCCN Clinical Practice Guidelines in Oncology. Journal of the National Comprehensive Cancer Network: JNCCN, 2017, 15, 926-957. | 4.9 | 451 |
| 2 | HIV-1 infects multipotent progenitor cells causing cell death and establishing latent cellular reservoirs. Nature Medicine, 2010, 16, 446-451. | 30.7 | 279 |
| 3 | NCCN Guidelines Insights: Acute Myeloid Leukemia, Version 2.2021. Journal of the National Comprehensive Cancer Network: JNCCN, 2021, 19, 16-27. | 4.9 | 170 |
| 4 | Mechanisms of resistance to tyrosine kinase inhibitors in chronic myeloid leukemia and recent therapeutic strategies to overcome resistance. Hematology American Society of Hematology Education Program, 2009, 2009, 461-476. | 2.5 | 153 |
| 5 | HIV-1 Utilizes the CXCR4 Chemokine Receptor to Infect Multipotent Hematopoietic Stem and Progenitor Cells. Cell Host and Microbe, 2011, 9, 223-234. | 11.0 | 103 |
| 6 | CD133+ Hematopoietic Progenitor Cells Harbor HIV Genomes in a Subset of Optimally Treated People With Long-Term Viral Suppression. Journal of Infectious Diseases, 2013, 207, 1807-1816. | 4.0 | 51 |
| 7 | CD4 is expressed on a heterogeneous subset of hematopoietic progenitors, which persistently harbor CXCR4 and CCR5-tropic HIV proviral genomes in vivo. PLoS Pathogens, 2017, 13, e1006509. | 4.7 | 42 |
| 8 | FLT3 mutational status is an independent risk factor for adverse outcomes after allogeneic transplantation in AML. Bone Marrow Transplantation, 2016, 51, 511-520. | 2.4 | 40 |
| 9 | Genome-Wide Single-Nucleotide Polymorphism Array Analysis Improves Prognostication of Acute Lymphoblastic Leukemia/Lymphoma. Journal of Molecular Diagnostics, 2016, 18, 595-603. | 2.8 | 36 |
| 10 | Hematopoietic Stem and Progenitor Cells Are a Distinct HIV Reservoir that Contributes to Persistent Viremia in Suppressed Patients. Cell Reports, 2018, 25, 3759-3773.e9. | 6.4 | 33 |
| 11 | The pre-clinical development of MDM2 inhibitors in chronic lymphocytic leukemia uncovers a central role for p53 status in sensitivity to Mdm2 inhibitor-mediated apoptosis. Cell Cycle, 2008, 7, 971-979. | 2.6 | 25 |
| 12 | Safety and efficacy of vismodegib in relapsed/refractory acute myeloid leukaemia: results of a phase Ib trial. British Journal of Haematology, 2019, 185, 595-598. | 2.5 | 19 |
| 13 | Maintenance sorafenib in FLT3-ITD AML following allogeneic HCT favorably impacts relapse and overall survival. Bone Marrow Transplantation, 2019, 54, 1518-1520. | 2.4 | 18 |
| 14 | Fibroblast Growth Factor 23â€“Induced Hypophosphatemia in Acute Leukemia. Journal of the Endocrine Society, 2018, 2, 437-443. | 0.2 | 14 |
| 15 | Impact of antibacterial prophylaxis during reinduction chemotherapy for relapse/refractory acute myeloid leukemia. Supportive Care in Cancer, 2017, 25, 541-547. | 2.2 | 9 |
| 16 | Intrathecal alemtuzumab: a potential treatment of refractory leptomeningeal T-cell prolymphocytic leukemia. Blood Advances, 2019, 3, 3333-3336. | 5.2 | 8 |
| 17 | Successful use of high-dose cytarabine in a patient with acute myeloid leukemia and severe hepatic dysfunction. Journal of Oncology Pharmacy Practice, 2016, 22, 811-815. | 0.9 | 5 |
| 18 | Considering baseline factors and early response rates to optimize therapy for chronic myeloid leukemia in chronic phase. Leukemia and Lymphoma, 2016, 57, 1002-1014. | 1.3 | 5 |

| # | ARTICLE | IF | CITATIONS |
|----|--|-----|-----------|
| 19 | A diagnosis of discernment: Identifying a novel ATRX mutation in myelodysplastic syndrome with acquired α -thalassemia. Cancer Genetics, 2019, 231-232, 36-40. | 0.4 | 3 |
| 20 | Lenalidomide Plus Hypomethylating Agent as a Treatment Option in Acute Myeloid Leukemia With Recurrent Genetic Abnormalities AML With inv(3)(q21.3q26.2) or t(3;3)(q21.3;q26.2); GATA2, MECOM. Clinical Lymphoma, Myeloma and Leukemia, 2020, 20, 24-30. | 0.4 | 3 |
| 21 | Real world use of FLT3 inhibitors for treatment of FLT3+ acute myeloid leukemia (AML): A single center, propensity-score matched, retrospective cohort study. Journal of Oncology Pharmacy Practice, 2022, 28, 1315-1325. | 0.9 | 2 |
| 22 | The Challenge of t(6;9) and FLT3-Positive Acute Myelogenous Leukemia in a Young Adult. Journal of Leukemia (Los Angeles, Calif), 2014, 02, . | 0.1 | 1 |
| 23 | Identification of variant APL translocations PRKAR1A-RAR Δ and ZBTB16-RAR Δ (PLZF-RAR Δ) through the MI-ONCOSEQ platform. Cancer Genetics, 2021, 258-259, 57-60. | 0.4 | 1 |
| 24 | 253. Febrile Neutropenia Antibiotic De-escalation Study in Acute Myeloid Leukemia Patients With Prolonged Neutropenia. Open Forum Infectious Diseases, 2018, 5, S107-S107. | 0.9 | 0 |
| 25 | Prevalence of bloodstream infections in neutropenic patients with bacteriuria. Infection Control and Hospital Epidemiology, 2019, 40, 955-956. | 1.8 | 0 |
| 26 | Hematopoietic Stem and Progenitor Cells (HSPCs). Methods in Molecular Biology, 2022, 2407, 115-154. | 0.9 | 0 |